We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+8.9%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$125M
Cap. Flow
+$100M
Cap. Flow %
7.26%
Top 10 Hldgs %
41.14%
Holding
237
New
73
Increased
38
Reduced
39
Closed
63

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$12.5M
2
ETNB
89bio
ETNB
+$10.8M
3
IMTX icon
Immatics
IMTX
+$6.72M
4
BMY icon
Bristol-Myers Squibb
BMY
+$6.02M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$5.91M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$15.7M
2
BTAI icon
BioXcel Therapeutics
BTAI
+$12.5M
3
KURA icon
Kura Oncology
KURA
+$10.1M
4
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$9.46M
5
ZGNX
Zogenix, Inc.
ZGNX
+$7.96M

Sector Composition

Rank Sector Weight
1 Healthcare 25.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVDL
151
DELISTED
Avadel Pharmaceuticals
AVDL
$275K 0.02%
54,694
-432,449
-89% -$3.15M
BLU
152
DELISTED
BELLUS Health Inc.
BLU
$227K 0.02%
+100,000
New +$284K
TPST icon
153
Tempest Therapeutics
TPST
$13.7M
$220K 0.02%
693
– –
TCDA
154
DELISTED
Tricida, Inc. Common Stock
TCDA
$210K 0.02%
23,193
-153,809
-87% -$2.25M
ARGX icon
155
PUT
argenx
ARGX
$53.4B
$209K 0.02%
800
-125,000
-99% -$30.1M
HZNP
156
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$205K 0.01%
+2,641
New +$182K
KURA icon
157
Kura Oncology
KURA
$800M
$189K 0.01%
6,203
-459,416
-99% -$10.1M
DRNA
158
CALL
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$179K 0.01%
10,000
-15,500
-61% -$321K
DRNA
159
PUT
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$179K 0.01%
10,000
– –
IVA
160
Inventiva
IVA
$1.06B
$177K 0.01%
+15,000
New +$172K
RAPT
161
CALL
DELISTED
RAPT Therapeutics
RAPT
$170K 0.01%
+663
New +$147K
QNCX icon
162
CALL
Quince Therapeutics
QNCX
$22.9M
$150K 0.01%
+15
New +$136K
QNCX icon
163
PUT
Quince Therapeutics
QNCX
$22.9M
$150K 0.01%
+15
New +$136K
MESO
164
PUT
Mesoblast
MESO
$1.84B
$145K 0.01%
+3,900
New +$122K
BTAI icon
165
BioXcel Therapeutics
BTAI
$24.9M
$117K 0.01%
170
-16,631
-99% -$12.5M
GBT
166
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
$117K 0.01%
2,100
-100,000
-98% -$6.36M
OVID icon
167
CALL
Ovid Therapeutics
OVID
$414M
$92K 0.01%
+16,000
New +$107K
DTIL icon
168
Precision BioSciences
DTIL
$180M
$55K ﹤0.01%
294
– –
MITO
169
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$50K ﹤0.01%
37,597
– –
ALPN
170
DELISTED
Alpine Immune Sciences Inc
ALPN
$41K ﹤0.01%
4,739
– –
APTO
171
DELISTED
Aptose Biosciences, Inc.
APTO
$23K ﹤0.01%
+9
New +$22.4K
ALEC icon
172
Alector
ALEC
$168M
$3K ﹤0.01%
+321
New +$5.19K
TNGX icon
173
Tango Therapeutics
TNGX
$4.43B
$2K ﹤0.01%
+250
New +$2.55K
CCXI
174
DELISTED
ChemoCentryx, Inc.
CCXI
$1K ﹤0.01%
+37
New +$1.99K
ADVM
175
DELISTED
Adverum Biotechnologies
ADVM
– –
-2,284
Closed -$342K
5 6
7
8 9

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Ikarian Capital held 237 positions worth $1.38B, up 10% from $1.26B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Ikarian Capital deployed $100M of net new capital in Q3 2020, opening 73 new positions and adding to 38 existing holdings. Its largest new stake was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 25% a quarter earlier.

On the sell side, the largest reduction was BioXcel Therapeutics, an estimated $12.5M trimmed.

  • Ikarian Capital's largest Q3 2020 buy was Milestone Pharmaceuticals: 1,743,545 shares worth $12.8M.
  • Ikarian Capital added most to Kiniksa Pharmaceuticals in Q3 2020, an estimated $5.91M increase.
  • Ikarian Capital's biggest Q3 2020 reduction was BioXcel Therapeutics, cutting an estimated $12.5M.
  • Ikarian Capital fully exited Blueprint Medicines in Q3 2020, selling an estimated $15.7M.
  • Ikarian Capital's ten largest holdings make up 41% of its $1.38B portfolio in Q3 2020.
  • Ikarian Capital opened 73 new positions and closed 63 in Q3 2020.
  • Ikarian Capital's portfolio value rose 10% quarter-over-quarter to $1.38B.

Based on Ikarian Capital's 13F filing for Q3 2020, filed 16 Nov 2020.